Latest News
| Munroe Regional Medical Center Performs 100th TIF Procedure |
| Friday, May 8, 2009 |
| Redwood City, CA (May 7, 2009) – EndoGastric Solutions (EGS), the recognized leader in the emerging field of Natural Orifice Surgery (NOS), today announced that Munroe Regional Medical Center, in Ocala, Florida, has performed 100 TIF (Transoral Incisionless Fundoplication) procedures for the treatment of chronic acid reflux, or gastroesophageal reflux |
| EndoGastric Solutions Finalizes Expansion of Commercial Organization |
| Friday, April 17, 2009 |
| Redwood City, CA (April 17, 2009) — EndoGastric Solutions (EGS), the recognized leader in the emerging field of Natural Orifice Surgery (NOS), today announced completion of an important sales and marketing expansion to support its growing commercialization success. EGS also announced the appointment of Tom Dempsey as Vice President of U.S. Sales, effective |
| SAGES Issues Position Statement Supporting Endolumenal Therapies for GERD and Obesity |
| Friday, April 10, 2009 |
| Redwood City, CA (April 10, 2009) — EndoGastric Solutions (EGS), the recognized leader in the emerging field of Natural Orifice Surgery (NOS), today announced its support of SAGES (the Society of American Gastrointestinal and Endoscopic Surgeons) Position Statement on Endolumenal Therapies for Gastrointestinal Diseases including GERD and Obesity published |
| Published Study Supports Two-Year Safety and Efficacy of Incisionless TIF Surgery for the Treatment of GERD |
| Thursday, March 26, 2009 |
| Redwood City, CA (March 26, 2009) — EndoGastric Solutions (EGS), the recognized leader in the emerging field of Natural Orifice Surgery (NOS), today announced publication of a two-year study of TIF (Transoral Incisionless Fundoplication) procedure for the surgical treatment of GERD (gastroesophageal reflux disease) confirming the procedure’s safety and |
| EndoGastric Solutions Announces Shipping Over 700 New EsophyX2 Devices |
| Friday, February 20, 2009 |
| Redwood City, CA (February 20, 2009) — EndoGastric Solutions (EGS), the recognized leader in the emerging field of Natural Orifice Surgery (NOS), today announced that over 700 EsophyX2 devices have shipped worldwide. The next generation of its innovative EsophyX® device, EsophyX2 facilitates the creation of a robust, tight antireflux valve with the TIF®2 |
| 27 New Medical Centers Join Growing List of U.S. Sites Performing NOS EsophyX or StomaphyX Procedures |
| Wednesday, January 28, 2009 |
| Redwood City, CA (January 28, 2009) — EndoGastric Solutions® (EGS), the recognized leader in the emerging field of Natural Orifice Surgery (NOS), today announced that 15 new U.S. medical centers performed their first TIF® (Transoral Incisionless Fundoplication) surgical procedures for the treatment of GERD (Gastroesophageal Reflux Disease) last quarter |
| Transoral Incisionless Fundoplication (TIF) Procedure With EsophyX Device Provides New Treatment Option for Children Suffering from Chronic GERD |
| Friday, January 9, 2009 |
| Redwood City, CA (January 9, 2009) —You don’t have to be an adult to suffer from the often debilitating effects of chronic acid reflux disease, also known as GERD, or gastroesophageal reflux disease. According to recent statistics, GERD is much more common among children than you might imagine. Until recently, the treatment options available to children |
| EGS Launches 12 New Incisionless Orifice Surgery Centers in September |
| Monday, October 20, 2008 |
| Redwood City, CA (October 17, 2008) — EndoGastric Solutions® (EGS), the recognized leader in the emerging field of Natural Orifice Surgery (NOS), today announced that five new surgery centers performed their first TIF® (Transoral Incisionless Fundoplication) surgical procedures for the treatment of GERD (Gastroesophageal Reflux Disease). The procedures were |
NP01937-01A